NewGen acquires preclinical oncology programmes from Kanion
This article was originally published in Scrip
Executive Summary
NewGen Therapeutics has acquired three preclinical small-molecule oncology development programmes from Kanion USA in Kanion Pharmaceuticals Co Ltd in Lianyungang, China.